157Gd-DOTA-PSMA as theranostic bio-gadolinium agent for prostate cancer targeted gadolinium neutron capture therapy
Journal of Cancer Research and Clinical Oncology · 2025
DOI: 10.1007/s00432-025-06136-7 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cancer Research and Clinical Oncology, 2025. Verfasst von Liang Xie und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, The Second Affiliated Hospital of Anhui Medical University, Hefei, 230601, Anhui, China. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Neutron Capture Therapy, Organometallic Compounds, Gadolinium. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: University Natural Science Research Project of Anhui Province, Clinical Research Cultivation Program of The Second Affiliated Hospital of Anhui Medical University.
Abstract (Originalsprache)
Gadolinium-neutron capture therapy (Gd-NCT) employs isotopically enriched Gadolinium (Gd) and thermal neutrons to selectively target cancer cells. This study investigated the targeting efficacy of 157Gd-DOTA-PSMA (Prostate-Specific Membrane Antigen) in prostate cancer and explored its potential applications in Gd-NCT. We developed 157Gd-DOTA-PSMA, a novel theranostic bio-gadolinium agent specifically designed for magnetic resonance imaging (MRI)-guided Gd-NCT. 68 Ga-DOTA-PSMA positron emission tomography-computed tomography (PET/CT) imaging showed peak radiotracer uptake at 2 h post-injection, with a tumor-to-non-tumor (T/NT) ratio of 6.95 ± 0.60. MRI analysis confirmed a stable T1 signal enhancement 2 h post-injection. Time-of-flight inductively coupled plasma mass spectrometry (TOF-ICP-MS) revealed significantly elevated Gd concentrations in 22Rv1 tumor compared to PC-3 tumor and other healthy organs. ICP-MS analysis showed Gd concentrations of 165.69 μg [Gd]/g in 22Rv1 tumors and 35.25 μg [Gd]/g in blood, yielding a tumor-to-blood (T/B) ratio of 4.65 ± 0.54 and a T/NT ratio of 3.65 ± 0.49. Neutron irradiation with 157Gd-DOTA-PSMA reduced cell viability, inhibited colony formation, and induced DNA damage and apoptosis in 22Rv1 cells. In 22Rv1 mice, γ-H2AX levels peaked at 6 h post-irradiation, accompanied by an increase in pro-apoptotic proteins and a decrease in anti-apoptotic proteins over 24 h. In the NCT group following the injection of 157Gd-DOTA-PSMA, there was effective suppression of tumor growth without a loss of body weight, resulting in a 1.7-fold increase in median survival compared to control group. 157Gd-DOTA-PSMA, as a theranostic bio-gadolinium agent designed for targeted Gd-NCT in prostate cancer, represents a novel therapeutic approach and broadens the scope of potential applications of neutron capture therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nuclear Medicine, The Second Affiliated Hospital of Anhui Medical University, Hefei, 230601, Anhui, China.
- School of Basic Medical Sciences, Anhui Medical University, Hefei, 230032, Anhui, China.
- School of Second Clinical Medical, Anhui Medical University, Hefei, 230032, Anhui, China.
- Department of Oncology, The Second Affiliated Hospital of Anhui Medical University, Hefei, 230601, Anhui, China.
- Department of Urology, The Second Affiliated Hospital of Anhui Medical University, Hefei, 230601, Anhui, China.
- Institute of Plasma Physics, Hefei Institutes of Physical Science, Chinese Academy of Sciences, HefeiAnhui, 230031, China.
Förderung
- University Natural Science Research Project of Anhui Province
- Clinical Research Cultivation Program of The Second Affiliated Hospital of Anhui Medical University
Zitieren
APA
Xie, L., Qin, J., Song, C., Yin, J., Wu, R., Chen, H., Dong, Y., Wang, N., Chen, L., Hong, B., Chen, N., Lu, P., Li, F., & Pang, X. (2025). 157Gd-DOTA-PSMA as theranostic bio-gadolinium agent for prostate cancer targeted gadolinium neutron capture therapy. Journal of Cancer Research and Clinical Oncology. https://doi.org/10.1007/s00432-025-06136-7
Vancouver
Xie L, Qin J, Song C, Yin J, Wu R, Chen H, et al. 157Gd-DOTA-PSMA as theranostic bio-gadolinium agent for prostate cancer targeted gadolinium neutron capture therapy. Journal of Cancer Research and Clinical Oncology. 2025. doi:10.1007/s00432-025-06136-7
BibTeX
@article{Xie2025,
author = {Xie, Liang and Qin, Jialin and Song, Cuiping and Yin, Jianchun and Wu, Ruixue and Chen, Hong and Dong, Yujie and Wang, Nianfei and Chen, Lei and Hong, Bing and Chen, Ni and Lu, Peng and Li, Fei and Pang, Xiaoxi},
title = {157Gd-DOTA-PSMA as theranostic bio-gadolinium agent for prostate cancer targeted gadolinium neutron capture therapy},
journal = {Journal of Cancer Research and Clinical Oncology},
year = {2025},
doi = {10.1007/s00432-025-06136-7}
}
EUVIMED